Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.41 |
| ▸ | PSMG3 | Q9BT73 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9752628 | 0.85 | CYP3A4 (0.52) | KCNA3CYP3A4PSMG3ABCB1 | |
| SCHEMBL21931371 | 0.85 | CYP3A4 (0.47) | KCNA3CYP3A4IMPDH2PSMG3ABCB1 | |
| SCHEMBL25952538 | 0.85 | CYP3A4 (0.52) | KCNA3CYP3A4PSMG3ABCB1 | |
| SCHEMBL25952524 | 0.85 | CYP3A4 (0.52) | KCNA3CYP3A4PSMG3ABCB1 | |
| SCHEMBL678486 | 0.84 | KCNA3 (0.53) | KCNA3CYP3A4 | |
| SCHEMBL29745831 | 0.83 | CYP3A4 (0.46) | KCNA3CYP3A4PSMG3ABCB1 | |
| SCHEMBL11106706 | 0.83 | CYP3A4 (0.48) | KCNA3CYP3A4IMPDH2PSMG3 | |
| SCHEMBL16666701 | 0.81 | CYP3A4 (0.52) | KCNA3CYP3A4IMPDH2PSMG3ABCB1 | |
| SCHEMBL11121530 | 0.79 | CYP3A4 (0.44) | KCNA3CYP3A4 | |
| SCHEMBL9752570 | 0.79 | CYP3A4 (0.44) | KCNA3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | TOHOKU UNIVERSITY (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | JAPAN ROYAL JELLEY CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | CHAT, ACHE, PSEN1 | KCNA3 4482/4885CYP3A4 4098/4885IMPDH2 3786/4885 |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | CHAT, ACHE, PSEN1 | KCNA3 4482/4885CYP3A4 4098/4885IMPDH2 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.